Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

NCT01921790 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions

BIOLOGICAL: Avastin
DRUG: Gemcitabine
DRUG: Oxaliplatin
DRUG: Pegaspargase
DRUG: Dexamethasone

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]